Galmed Pharmaceuticals Ltd. filings document the company’s foreign private issuer reporting, Aramchol development disclosures and public-company governance matters. Recent Form 6-K reports furnish press releases on Aramchol-based collaborations, brain-penetrating formulation work, scientific presentations, Nasdaq minimum bid price correspondence and shareholder meeting materials.
The filing record also includes proxy and voting materials for special general meetings, incorporation of selected 6-K disclosures into Form S-8 and Form F-3 registration statements, and references to the company’s ordinary shares. These documents describe governance procedures, capital-market registration matters, listing-status communications and development updates for Galmed’s clinical-stage biopharmaceutical business.
Galmed Pharmaceuticals Ltd. reported interim financial details as of June 30, 2025. The company held $7.5 million in short-term deposits, $0.1 million in restricted cash and $8.1 million in marketable debt securities. Investment in an associate is shown at $1.593 million (down from $2.119 million). Trade payables were $1.369 million. Ordinary shares outstanding increased to 5,303,050 from 1,664,884, reflecting multiple issuances during the period. The company reported an accumulated deficit of $204.1 million and operating expenses for the period (total operating expenses shown at $2,109 thousand). The filing discloses multiple equity financings including a SEPA commitment, ATM sales totaling approximately $7.7 million gross, and proceeds of approximately $5.1 million from issuances to YA.
Galmed Pharmaceuticals reports several corporate updates. The company issued a press release announcing a new digital asset management strategy aimed at enhancing capital efficiency and driving shareholder value. Galmed also terminated a previously announced binding term sheet with Entomus s.r.o. for an exclusive license to develop and commercialize a Self-Emulsifying Drug Delivery System (SEDDS) formulation. Instead, a new UK-based company has been formed to pursue the SEDDS project, and it is contemplated that Galmed will acquire up to 25% of this entity’s share capital, subject to definitive agreements and board approval. The company additionally filed supplemental risk factor disclosures that update prior risk discussions and incorporated these materials into its existing Form S-8 and Form F-3 registration statements.
Galmed Pharmaceuticals Ltd. reports that its shareholders approved an amended and restated set of articles of association at a Special General Meeting held on August 15, 2025. The proposal was described in a previously distributed proxy statement and was approved with the requisite majority under Israeli Companies Law. The updated articles of association are provided as an exhibit and this report is incorporated by reference into Galmed’s existing Form S-8 and Form F-3 registration statements.
CVI Investments, Inc. and Heights Capital Management, Inc. disclosed a beneficial position in Galmed Pharmaceuticals Ltd. consisting of 173,333 ordinary shares, equal to 7.1% of the class based on 2,258,034 shares outstanding as reported by the company as of March 31, 2025. The reported position represents shares issuable upon exercise of warrants, and the warrants include an exercise limitation that prevents exercises that would push ownership above 9.99%. Heights Capital serves as investment manager to CVI and may have shared voting and dispositive power over the reported shares; both reporting persons disclaim beneficial ownership except for their pecuniary interest.